Locust Walk conducted a multi‑year analysis of JPM‑week deal activity to evaluate whether early‑January partnering and M&A activity can reliably benchmark and anticipate full‑year dealmaking momentum across global biopharma.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Year-In-Review Report applies the latest data to analyze the current landscape in life sciences deals.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Q3 Report applies the latest data to analyze the current landscape in life sciences deals.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Q2 Report applies the latest data to analyze the current landscape in life sciences deals.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Q1 Report applies the latest data to analyze the current landscape in life sciences deals.
Locust Walk analyzed the evolving landscape of China’s biotech out-licensing market and its impact on global dealmaking.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings.
Locust Walk’s Overview of AI in Biotech report discusses how AI has profoundly impacted drug discovery and the pharmaceutical industry in the last five years, with AI-derived assets representing nearly half of the preclinical pipeline.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Year-In-Review Report applies the latest data to analyze current activities in the life sciences deal landscape.